Top Health Insurance Plans Expanded Coverage of the Verifi® Non-Invasive Prenatal Test to Detect Down Syndrome & Other

  Top Health Insurance Plans Expanded Coverage of the Verifi® Non-Invasive
  Prenatal Test to Detect Down Syndrome & Other Chromosomal Abnormalities

          Coverage increases access to over 80 million covered lives

Business Wire

WALTHAM, Mass. & REDWOOD CITY, Calif. -- May 14, 2013

PerkinElmer, Inc. (NYSE: PKI), a global leader in maternal and fetal health,
and Verinata Health, an Illumina company and innovator of non-invasive
prenatal tests (NIPT), today announced that several of the top health
insurance plans have expanded coverage of the verifi^® prenatal test for a
variety of potential fetal health risks to over 80 million covered lives. The
verifi^® test is among the recently covered DNA-based NIPTs that detect
multiple fetal chromosomal aneuploidies, an abnormal number of chromosomes, in
high-risk pregnancies. Coverage of NIPTs provides expecting parents with
better access to high quality screening for fetal health. Earlier this year,
PerkinElmer and Verinata announced their collaboration to expand access to
Verinata’s verifi^® test in the U.S.

“PerkinElmer is focused on enabling early access for mothers and babies to the
most advanced testing solutions,” said Robert Friel, chairman and chief
executive officer, PerkinElmer. “Health insurance plans believe in the
clinical utility of this advanced test. We are excited with the early success
we are having in expanding access to the verifi^® prenatal test with top
health insurance plans. We now have contracts with more than 15 health plans
and recently signed agreements with two of the top five providers, increasing
access to greater than 80 million covered lives. As plans are rapidly
accepting non-invasive testing into medical policy coverage, we anticipate
further coverage of verifi^® by our existing 260 health plan contracts.”

The verifi^® prenatal test uses a single maternal blood sample, taken as early
as 10 weeks of pregnancy, to detect the most common fetal chromosome
abnormalities. It is specifically designed for women who will be 35 or older
at delivery, women with a prior personal or family history of chromosome
abnormalities, pregnancies that have received abnormal biochemical screening
results, and pregnancies showing ultrasound abnormalities.

DNA-based NIPTs of fetal aneuploidies are clinically-proven as screening tools
for Down syndrome, Edwards syndrome and Patau syndrome for high-risk
pregnancies. As with any NIPT assessment for fetal aneuploidy, the
confirmation via an invasive procedure is recommended for positive results.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including, but not
limited to, statements relating to estimates and projections of future
earnings per share, cash flow and revenue growth and other financial results,
developments relating to our customers and end-markets, and plans concerning
business development opportunities and divestitures. Words such as "believes,"
"intends," "anticipates," "plans," "expects," "projects," "forecasts," "will"
and similar expressions, and references to guidance, are intended to identify
forward-looking statements. Such statements are based on management's current
assumptions and expectations and no assurances can be given that our
assumptions or expectations will prove to be correct. A number of important
risk factors could cause actual results to differ materially from the results
described, implied or projected in any forward-looking statements. These
factors include, without limitation: (1) markets into which we sell our
products declining or not growing as anticipated; (2) fluctuations in the
global economic and political environments; (3) our failure to introduce new
products in a timely manner; (4) our ability to execute acquisitions and
license technologies, or to successfully integrate acquired businesses and
licensed technologies into our existing business or to make them profitable,
or successfully divest businesses; (5) our failure to adequately protect our
intellectual property; (6) the loss of any of our licenses or licensed rights;
(7) our ability to compete effectively; (8) fluctuation in our quarterly
operating results and our ability to adjust our operations to address
unexpected changes; (9) significant disruption in third-party package delivery
and import/export services or significant increases in prices for those
services; (10) disruptions in the supply of raw materials and supplies; (11)
the manufacture and sale of products exposing us to product liability claims;
(12) our failure to maintain compliance with applicable government
regulations; (13) regulatory changes; (14) our failure to comply with
healthcare industry regulations; (15) economic, political and other risks
associated with foreign operations; (16) our ability to retain key personnel;
(17) significant disruption in our information technology systems; (18) our
ability to obtain future financing; (19) restrictions in our credit
agreements; (20) our ability to realize the full value of our intangible
assets; (21) significant fluctuations in our stock price; (22) reduction or
elimination of dividends on our common stock; and (23) other factors which we
describe under the caption "Risk Factors" in our most recent annual report on
Form 10-K and in our other filings with the Securities and Exchange
Commission. We disclaim any intention or obligation to update any
forward-looking statements as a result of developments occurring after the
date of this press release.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and
safety of people and the environment. The company reported revenue of
approximately $2.1 billion in 2012, has about 7,500 employees serving
customers in more than 150 countries, and is a component of the S&P 500 Index.
Additional information is available through 1-877-PKI-NYSE, or at

About Verinata Health

Verinata (, a wholly-owned subsidiary of Illumina, Inc., is
driven by a sole, extraordinary purpose - maternal and fetal health. Our
initial focus is to develop and offer non-invasive tests for early
identification of fetal chromosomal abnormalities using our proprietary
technologies. We aim to reduce the anxiety associated with today's multi-step
process, the unacceptable false-positive rates, the non-specific and sometimes
confusing results of current prenatal screening methods, as well as the risk
of current invasive procedures. We support national guidelines and the recent
American College of Obstetricians and Gynecologists and the Society for
Maternal-Fetal Medicine Committee Opinion recommending cell-free DNA prenatal
testing is one option that can be used as a primary or secondary screening
test in women at increased risk of aneuploidy. We believe women who desire
such testing should be offered a single blood draw test with a definitive
result. The verifi® prenatal test is available through a physician.


PerkinElmer, Inc.
Investor Relations:
Tommy J. Thomas, 781-663-5889
Media Contact:
Stephanie R. Wasco, 781-663-5701
Illumina, Inc.
Rebecca Chambers, 858-255-5243
Jennifer Temple, 858-882-6822
Press spacebar to pause and continue. Press esc to stop.